Flag of the European Union EU Clinical Trials Register Help

Clinical trials for janssen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,458 result(s) found for: janssen. Displaying page 1 of 73.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003191-14 Sponsor Protocol Number: 21CH135 Start Date*: 2021-08-16
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Jan...
    Medical condition: volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000289-67 Sponsor Protocol Number: CNTO1275AKS3003 Start Date*: 2015-06-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloa...
    Medical condition: Nonradiographic Axial Spondylitis, Ankylosing
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004889-15 Sponsor Protocol Number: R092670PSY3011 Start Date*: 2012-04-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) BE (Completed) DE (Completed) PT (Completed) AT (Completed) SE (Completed) DK (Prematurely Ended) SK (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-003781-14 Sponsor Protocol Number: RISBIM3003 Start Date*: 2004-12-02
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder,...
    Medical condition: BIPOLAR MANIA
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004857-27 Sponsor Protocol Number: F20REWARDLU Start Date*: 2008-01-02
    Sponsor Name:Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich
    Full Title: Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone
    Medical condition: schizophrenic patients (F20.0, F20.1, F20.2, F20.3, F20.5, F20.6, F20.8, F20.9) and healthy controls
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004482-15 Sponsor Protocol Number: NRA 1280013 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Aachen, Klinik f. Psychiatrie und Psychotherapie
    Full Title: Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.
    Medical condition: Patienten mit DSM-IVTR diagnostizierter Schizophrenie
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002630-36 Sponsor Protocol Number: P1090 Start Date*: 2014-02-25
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) [...]
    1. The National Institute of Allergy and Infectious Diseases (NIAID)
    2. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: A PHASE I/II, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF ETRAVIRINE (ETR) IN ANTIRETROVIRAL (ARV) TREATMENT-EXPERIENCED HIV-1 INFECTED INFANT...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000475-21 Sponsor Protocol Number: 67896049PUH3001 Start Date*: 2021-03-31
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants who Participated in a Previous Selexipag Study.
    Medical condition: Pulmonary Hypertension.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000288-16 Sponsor Protocol Number: CNTO1275AKS3002 Start Date*: 2015-08-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiogra...
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) PL (Completed) BG (Prematurely Ended) GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015931-33 Sponsor Protocol Number: 42801PAI3010 Start Date*: 2010-05-07
    Sponsor Name:JANSSEN-CILAG
    Full Title: An open label, prospective, multicenter, single-arm clinical trial to investigate the safety and the analgesic effectiveness of a low dose (4 mg) OROS hydromorphone hydrochloride as starting dose...
    Medical condition: patients with chronic moderate to severe malignant pain which has not been adequately controlled by previous treatment with NSAIDs, COX-2 inhibitors or paracetamol.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002560-73 Sponsor Protocol Number: SWITCH_ON Start Date*: 2022-09-01
    Sponsor Name:Erasmus MC
    Full Title: SWITCH ON: Analysing the immunogenicity of additional booster vaccinations in healthcare workers.
    Medical condition: To study the necessity to boost healthcare workers (which arre representative for the dutch population) with a COVID vaccin by measuring the immunogenicity at 7 days and 28 days..
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003593-85 Sponsor Protocol Number: VX-950HPC3005 Start Date*: 2012-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibro...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) HU (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003679-48 Sponsor Protocol Number: CNTO1275AKS3001 Start Date*: 2015-12-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF alpha Naive Subjects With Active Radiograph...
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000225-12 Sponsor Protocol Number: CNTO148DML1001 Start Date*: 2017-08-01
    Sponsor Name:Janssen Biologics BV
    Full Title: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Medical condition: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-001510-15 Sponsor Protocol Number: CNTO1959UCO2002 Start Date*: 2019-05-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and G...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005243-28 Sponsor Protocol Number: 212082PCR3010 Start Date*: 2012-03-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004835-10 Sponsor Protocol Number: R092670SCH3015 Start Date*: 2016-03-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039636 Schizophrenia simple PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) DK (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000870-29 Sponsor Protocol Number: RISSCH3001 Start Date*: 2004-11-04
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness
    Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000121-40 Sponsor Protocol Number: CNTO1275PSO3013 Start Date*: 2016-05-02
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pedia...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) PL (Completed) FR (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 14:55:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA